B/HPIV3/S-6P / National Institute of Allergy and Infectious Diseases, Johns Hopkins Bloomberg School of Public Health - LARVOL DELTA

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters. (PubMed, bioRxiv) - "Here, we evaluated in the hamster model the immunogenicity, breadth of immunity, and durability of protection elicited by co-administration of two live-attenuated bovine/human parainfluenza virus type 3 (B/HPIV3) vectors expressing antigenically distinct prefusion stabilized S proteins of the ancestral SARS-CoV-2 isolate (B/HPIV3/S-6P) or the Omicron/BA.5 variant (B/HPIV3/S-BA.5-2P)...Thus, in the hamster model, intranasal immunization with live-attenuated B/HPIV3 expressing SARS-CoV-2 S can provide durable protection for several months, and combining two antigenically distinct B/HPIV3 S-expressing vectors substantially broadens the antibody response. This mucosal immunization approach may better protect against infection from emerging SARS-CoV-2 variants."

Journal • Preclinical • Infectious Disease • Inflammation • Novel Coronavirus Disease • Otorhinolaryngology • Pediatrics • Respiratory Diseases • PROS1

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases